Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Switzerland Agency Approves Moderna and Pfizer/BioNTech Boosters

10/26/2021 | 11:56am EST

By Josh Beckerman

Switzerland's Swissmedic agency has approved Covid-19 vaccine booster doses from Moderna Inc. and from Pfizer Inc. and BioNTech SE.

Swissmedic said a third vaccination at least six months after the second dose may help "older people or at-risk patients" maintain their level of protection. For immunocompromised people, such as organ transplant recipients, who have a weak immune response or none at all after two doses, a third dose can be administered at least 28 days after the second shot, the agency said.

On Monday, Moderna said the European Medicines Agency's Committee for Medicinal Products for Human Use concluded that a 50 ug booster dose of its vaccine may be considered for people aged 18 and older at least six months after completion of primary vaccination. The EMA's opinion reflected favorable results from a data analysis of a Phase 2 clinical study, Moderna said.

The U.S. Food and Drug Administration authorized Pfizer-BioNTech boosters in September. In October, it approved those from Moderna and Johnson & Johnson, and authorized "mix and match" use of a different booster vaccine.

In September 2020, Moderna said Switzerland would be the first country outside of North America with a Moderna regional hub and commercial organization.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-26-21 1356ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 3.17% 344.06 Delayed Quote.310.30%
MODERNA, INC. 1.73% 306.72 Delayed Quote.188.59%
PFIZER, INC. 2.32% 54.27 Delayed Quote.44.09%
All news about MODERNA, INC.
03:25pU.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
RE
03:16pU.S. CDC Says Delivered 580,893,145 Doses Of Covid-19 Vaccine As Of Dec 3
RE
03:15pU.S. CDC Reports Total Novel Coronavirus Cases Of 48,767,329 As Of Yesterday
RE
12:15pVaccine makers could make Omicron-specific booster, says Fauci
RE
12:02pPUMP / DUMP #13 : This week's gainers and losers
01:21aUK jabs deal to 'future-proof' immunisation
AQ
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
MT
12/02U.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
RE
12/02U.S. CDC Says Delivered 578,263,565 Doses Of COVID-19 Vaccine As Of Dec 2
RE
12/02US Stocks Rebound Following Recent Sell-Offs as Omicron Variant Concerns Subside
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,5x
Yield 2021 -
Capitalization 124 B 124 B -
EV / Sales 2021 6,42x
EV / Sales 2022 4,93x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 301,49 $
Average target price 272,53 $
Spread / Average Target -9,60%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745
ICON PUBLIC LIMITED COMPANY40.04%22 226